Clinical Trials
4 trialsNCT02498613 2026-05-01
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04090567 2026-03-05
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT00454805 2016-08-03
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.
AstraZeneca
Phase 2 Completed
NCT00244881 2015-12-07
A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)
National Cancer Institute (NCI)
Phase 2 Completed